Physician profile
James C Marsh
NPI 1588645915
$302.80
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $13.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $51.25 | 2019-2020 | |
| Amgen INC. | $42.66 | 2019 | |
| Genzyme Corporation | $26.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.52 | 2019 | |
| Celgene Corporation | $21.44 | 2019 | |
| Dova Pharmaceuticals | $19.50 | 2019 | |
| Eisai INC. | $19.29 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.58 | 2019 | |
| Gilead Sciences, INC. | $16.46 | 2019 | |
| Tesaro, INC. | $13.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.17 | 2019 | |
| Merck Sharp & Dohme LLC | $12.46 | 2019 | |
| Tactile Systems Technology INC | $12.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.